← Back to screener

Arbutus Biopharma Corp ABUS

Rank #2378 · Nasdaq · $0.8B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
21.4
P/E
-11.9
P/B
7.84
ROE
-66.0%
Op. Margin
-1236.7%
Debt Ratio
32%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -11.9x, P/B 7.84x. Ranks in the top 79% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -66.0%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 32%. Ranks in the top 17% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 66.0% year over year. Ranks in the top 98% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2013$0.0B$-0.0B$-0.0B$0.0B-63.6–
2014$0.0B$-0.0B$0.0B$0.0B-91.8240
2015$0.0B$-0.0B$-0.0B$0.0B-78.674
2016$0.0B$-0.0B$-0.0B$0.1B-223.6278
2017$0.0B$-0.1B$-0.1B$0.1B-446.583
2018$0.0B$-0.1B$-0.1B$0.2B-1036.727
2019$0.0B$-0.1B$-0.1B$0.2B-1510.215
2020$0.0B$-0.1B$-0.2B$0.2B-2394.016
2021$0.0B$-0.1B$-0.1B$0.1B-836.148
2022$0.0B$-0.1B$-0.1B$0.1B-669.134
2023$0.0B$-0.1B$-0.1B$0.2B-167.835
2024$0.0B$-0.1B$-0.1B$0.1B-430.528
2025$0.0B$-0.1B$-0.1B$0.1B-1236.732

← See the full screener